Skip to main content
BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%
AboutTraders FairTraders AwardsTrade Game
/
Prezzi
Inizia→
stocksJul 15, 2026, 10:27 AM

Johnson & Johnson Beats Q2 Estimates, Raises FY Guidance

Johnson & Johnson reported Q2 2026 adjusted EPS of $2.90, above the $2.85 estimate, and sales of $25.31B beating $25.04B. The company raised its full-year sales and adjusted EPS guidance.

JNJ

Johnson & Johnson (JNJ) reported Q2 2026 earnings that surpassed analyst expectations. Adjusted EPS came in at $2.90 versus the consensus estimate of $2.85. Revenue reached $25.31 billion, ahead of the $25.04 billion forecast.

Medtech sales totaled $8.93 billion, slightly below the estimated $8.99 billion. Medicine revenue was $16.38 billion, exceeding the $16.12 billion estimate.

The company raised its full-year 2026 guidance. FY sales are now seen at $100.8 billion to $101.4 billion, up from the prior range of $100.3 billion to $101.3 billion. FY adjusted EPS guidance was lifted to $11.60-$11.75 from $11.45-$11.65.

Source: First Squawk

Johnson & Johnson Beats Q2 Estimates, Raises FY Guidance — TradersWeek · TradersWeek